Financing ·
Neurogene Inc. entered into an underwriting agreement on June 30, 2026, to issue and sell 3,500,000 shares of common…
NGNENeurogene Inc.
Neurogene Inc. entered into an underwriting agreement on June 30, 2026, to issue and sell 3,500,000 shares of common stock at $30.00 per share and pre-funded warrants to purchase up to 666,666 shares at $29.999999 per warrant. Underwriters exercised their option to purchase an additional 624,999 shares. Net proceeds are expected to be approximately $134.8 million. Neurogene Inc. is a biotechnology company focused on gene therapy development.